NEW YORK (GenomeWeb) – BioTheranostics has named Nicolas Barthelemy its new president and CEO. He succeeds Richard Ding, who will remain chairman of the board of bioTheranostics in addition to heading the Asia Pacific operations for parent company bioMérieux. Barthelemy previously served as chief commercial officer and president of the Cell Systems Division.
RainDance Technologies has named John Luckey as its new vice president of product development.
Luckey has held senior product and platform development positions at companies such as Roche NimbleGen, where he directed research and development activities for improving and expanding the company's core DNA microarray synthesis technology and related instrumentation; and MJ Research, where he contributed to the design and development of the Opticon product family and Opticon Monitor software. While at Roche, he also liaised with 454 Life Sciences development teams and participated on the global team tasked with defining a strategy to apply next-generation sequencing technology to clinical diagnostics.
John Flannery has been named president and CEO of GE Healthcare. He starts the post immediately, taking over for John Dineen, who is leaving the firm. He most recently was senior vice president of business development for GE, leading business development activity related to the purchase of Alstom's energy and transmission businesses, the spinoff of Retail Finance, and the sale of GE Appliances. Prior to that, he was the president and CEO of GE India and a senior leader at GE Capital. Flannery has been with GE for 27 years.
Bruce Bodaken, Karin Eastham, and Jorge Garces have been appointed to the board of directors of molecular diagnostics firm AltheaDx.
Bodaken served as chairman and CEO of Blue Shield of California from January 2000 to December 2012, and he currently serves on the boards of directors of Rite Aid and WageWorks. He also is on the board of directors of the Institute of Medicine's Roundtable on Value and Science-Driven Healthcare, and is a visiting scholar at the Brookings Institution.
Eastham serves on the boards of directors of lllumina, Veracyte, MorphoSys, and Geron. She previously was executive VP, COO, and a member of the board of trustees of the Burnham Institute for Medical Research.
Garces has been president of AltheaDx since February 2014 and the firm's COO since June 2013. Prior to joining AltheaDx, he was senior VP of R&D at GenMark Diagnostics, CEO and president of Enigma Diagnostics, and VP and site operations manager of Hologic.
Paul Miller has joined synthetic biology firm Synlogic as its CSO. Also, Alison Silver joined the company as Chief Operating Officer. Miller has more than 20 years of experience in the pharmaceutical space and was previously VP of infection biology research at AstraZeneca. Before that, he held various positions at Pfizer. Silva was COO of SLA Pharma before joining Synlogic. Before that, she served as VP of drug development at Marina Biotech through its acquisition of Cequent Pharmaceuticals in 2010.
Essen BioScience, an Ann Arbor, Mich.-based developer of cell analysis instruments and reagents, has named Brett Williams its new president. He succeeds Kirk Schroeder, who will remain at the firm as VP of R&D.
Williams most recently served as VP and GM of the Cellular Analysis business unit at Thermo Fisher Scientific. He was VP and GM of Flow Cytometry and Imaging at Life Technologies, prior to that firm's acquisition by Thermo Fisher.
Myriad Genetics announced that R. Bryan Riggsbee will be its new executive VP, CFO, and treasurer starting October 16. In the interim, Jim Evans will continue to serve as CFO.
Prior to joining Myriad, Riggsbee was senior VP of corporate finance at Laboratory Corporation of America. Before that, he held various positions at General Electric and worked in the audit division at KPMG.
Promoted? Changing jobs? GenomeWeb wants to know. [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.